MX2017017155A - Antagonistas del receptor de tromboxano en erea/asma. - Google Patents

Antagonistas del receptor de tromboxano en erea/asma.

Info

Publication number
MX2017017155A
MX2017017155A MX2017017155A MX2017017155A MX2017017155A MX 2017017155 A MX2017017155 A MX 2017017155A MX 2017017155 A MX2017017155 A MX 2017017155A MX 2017017155 A MX2017017155 A MX 2017017155A MX 2017017155 A MX2017017155 A MX 2017017155A
Authority
MX
Mexico
Prior art keywords
aerd
asthma
thromboxane receptor
receptor antagonists
thromboxane
Prior art date
Application number
MX2017017155A
Other languages
English (en)
Inventor
Pavliv Leo
Original Assignee
Cumberland Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cumberland Pharmaceuticals Inc filed Critical Cumberland Pharmaceuticals Inc
Publication of MX2017017155A publication Critical patent/MX2017017155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a métodos para tratar la EREA (Enfermedad Respiratoria Exacerbada por la Aspirina) y/o el asma mediante la administración de un antagonista del receptor de tromboxano a un paciente que lo necesite.
MX2017017155A 2015-06-30 2016-06-28 Antagonistas del receptor de tromboxano en erea/asma. MX2017017155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186644P 2015-06-30 2015-06-30
PCT/US2016/039816 WO2017004040A1 (en) 2015-06-30 2016-06-28 Thromboxane receptor antagonists in aerd/asthma

Publications (1)

Publication Number Publication Date
MX2017017155A true MX2017017155A (es) 2018-08-09

Family

ID=57609035

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017017155A MX2017017155A (es) 2015-06-30 2016-06-28 Antagonistas del receptor de tromboxano en erea/asma.

Country Status (12)

Country Link
US (4) US20170000771A1 (es)
EP (1) EP3316882A4 (es)
JP (1) JP7033454B2 (es)
KR (2) KR20220137141A (es)
CN (2) CN107708692A (es)
AU (1) AU2016285566A1 (es)
BR (1) BR112017027298A2 (es)
CA (1) CA2990880A1 (es)
HK (1) HK1250916A1 (es)
MX (1) MX2017017155A (es)
WO (1) WO2017004040A1 (es)
ZA (1) ZA201708163B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9693998B2 (en) 2014-05-16 2017-07-04 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
EP3454850B1 (en) 2016-05-11 2023-06-21 Cumberland Pharmaceuticals Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2809377A1 (de) 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4537981A (en) 1981-11-09 1985-08-27 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane and 7-oxabicycloheptene compounds
US4416896A (en) 1982-05-17 1983-11-22 E. R. Squibb & Sons, Inc. 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease
US4663336A (en) 1985-07-01 1987-05-05 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease
US4752616A (en) 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use
US5066480A (en) 1988-04-11 1991-11-19 E. R. Squibb & Sons, Inc. Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist
US4839384A (en) 1988-10-07 1989-06-13 E. R. Squibb & Sons, Inc. Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
US5100889A (en) 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
JPH02273625A (ja) 1989-04-14 1990-11-08 Takeda Chem Ind Ltd 高エンドセリン症予防・治療剤
US4977174A (en) 1989-06-12 1990-12-11 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5128359A (en) 1990-02-16 1992-07-07 Laboratoires Upsa Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation
ZA911453B (en) 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
IL110376A (en) 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US6509348B1 (en) 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
WO2002083130A1 (en) 2001-04-16 2002-10-24 Bristol-Myers Squibb Company Enantiomers of n-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide
CA2491848A1 (en) * 2002-07-09 2004-01-15 B.M.R.A. Corporation B.V. Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
WO2006002073A2 (en) 2004-06-15 2006-01-05 Vanderbilt University Method for preventing heme-induced lipid peroxidation
DE102005001795A1 (de) * 2004-10-07 2006-04-13 Symrise Gmbh & Co. Kg Papierrollenhalter
US7358091B2 (en) * 2004-12-14 2008-04-15 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients
ATE537832T1 (de) 2005-06-10 2012-01-15 Dong A Pharm Co Ltd Mittel zur prävention und behandlung von lebererkrankungen mit einem pyrazolopyrimidin- derivat
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
WO2008128038A2 (en) 2007-04-13 2008-10-23 The Scripps Research Institute Methods and compositions for treating cardiac dysfunctions
EP2146573A4 (en) * 2007-05-03 2012-11-21 Portola Pharm Inc GALENIC FORMS IN UNIT DOSES AND METHODS OF TREATING AND PREVENTING THROMBOSIS USING THROMBOXANE RECEPTOR ANTAGONISTS
US8299097B2 (en) 2008-09-12 2012-10-30 The Brigham And Women's Hospital, Inc. Methods for treating inflammatory disorders
AU2011279144A1 (en) 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
WO2014039223A1 (en) * 2012-09-07 2014-03-13 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of aspirin-exacerbated respiratory disease (aerd)
US9693998B2 (en) 2014-05-16 2017-07-04 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
KR20190003573A (ko) 2016-04-27 2019-01-09 큠버랜드 파마슈티컬즈 인코포레이티드 전신 경화증을 위한 이페트로반 치료제
EP3454850B1 (en) 2016-05-11 2023-06-21 Cumberland Pharmaceuticals Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists
US20180050020A1 (en) 2016-08-22 2018-02-22 Cumberland Pharmaceuticals, Inc. Ifetroban treatment of portal hypertension

Also Published As

Publication number Publication date
US20220211674A1 (en) 2022-07-07
US20220218672A1 (en) 2022-07-14
ZA201708163B (en) 2018-11-28
CA2990880A1 (en) 2017-01-05
US11571412B2 (en) 2023-02-07
HK1250916A1 (zh) 2019-01-18
US20170000771A1 (en) 2017-01-05
EP3316882A4 (en) 2019-02-20
KR20180037951A (ko) 2018-04-13
EP3316882A1 (en) 2018-05-09
JP7033454B2 (ja) 2022-03-10
US20200155513A1 (en) 2020-05-21
KR102448406B1 (ko) 2022-09-27
KR20220137141A (ko) 2022-10-11
WO2017004040A1 (en) 2017-01-05
BR112017027298A2 (pt) 2018-09-04
AU2016285566A1 (en) 2017-12-14
CN114569608A (zh) 2022-06-03
CN107708692A (zh) 2018-02-16
JP2018519315A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
IL269444B (en) New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
GB2538682A (en) Nasal drug products and methods of their use
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
HUE044199T2 (hu) Inhalációs készülék légúti betegségek aeroszolos terápiájában való alkalmazásra
ZA201705874B (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
HK1243368A1 (zh) 丁丙诺啡给药方案
MX2016014696A (es) Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
MX369346B (es) Particulas inhalables que comprenden una combinacion de un anticolinergico, un corticosteroide y un beta-adrenergico.
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MY208219A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
IL264139A (en) Dosing regimens of LINGO-1 antagonists and uses for the treatment of demyelinating disorders
CY1123075T1 (el) Μεθοδος αγωγης και συνθεσεις που περιλαμβανουν εναν διπλο αναστολεα κινασης ρι3κ δελτα-γαμα και ενα κορτικοστεροειδες
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
MX2018003349A (es) Productos de farmaco nasal y metodos de su uso.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
NZ727876A (en) Misoprostol dispersible tablet
MA40574A (fr) Traitement de maladies fibrotiques
SI3649109T1 (sl) Etinilne spojine, njihova priprava in njihova terapevtska uporaba za zdravljenje malarije
HK1231767A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist